SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Core Insights - Sera Prognostics Inc. is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information [4] - The company will participate in two upcoming investor conferences, the William Blair 45th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference, both taking place from June 3 to June 5, 2025 [1][2] Company Overview - Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [4] - The company's mission is to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, aiming to reduce healthcare delivery costs [4] - Sera has a robust pipeline of innovative diagnostic tests, particularly focused on early prediction of preterm birth risk and other pregnancy complications [4] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [5] - The March of Dimes Report Card indicates that over one in ten infants in the U.S. has been born prematurely for the last six consecutive years [5] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [5] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [6] - This test measures and analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify women at increased risk during weeks 18 through 20 of pregnancy [6] - The PreTRM® Test enables more informed, personalized clinical decisions based on each woman's individual risk [6]